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The goal of these studies was to extensively characterize the first recombinant FIX therapeutic corresponding to the threonine-148
(Thr-148) polymorph, IXINITY (trenonacog alfa [coagulation factor IX (recombinant)]). Gel electrophoresis, circular dichroism,
and gel filtration were used to determine purity and confirm structure. Chromatographic and mass spectrometry techniques were
used to identify and quantify posttranslational modifications. Activity was assessed as the ability to activate factor X (FX) both with
and without factor VIIIa (FVIIIa) and in a standard clotting assay. All results were consistent across multiple lots. Trenonacog alfa
migrated as a single band on Coomassie-stained gels; activity assays were normal and showed <0.002 IU of activated factor IX (FIXa)
per IU of FIX. The molecule has >97% 𝛾-carboxylation and underwent the appropriate structural change upon binding calcium
ions. Trenonacog alfa was activated normally with factor XIa (FXIa); once activated it bound to FVIIIa and FXa. When activated
to FIXa, it was inhibited efficiently by antithrombin. Glycosylation patterns were similar to plasma-derived FIX with sialic acid
content consistent with the literature reports of good pharmacokinetic performance. These studies have shown that trenonacog
alfa is a highly pure product with a primary sequence and posttranslational modifications consistent with the common Thr-148
polymorphism of plasma-derived FIX.

1. Introduction
Human factor IX (FIX) is a vitamin K-dependent glycoprotein that circulates in plasma at a concentration of
approximately 4 𝜇g/mL. It is a 415 amino acid protein that
is synthesized in the liver and contains multiple posttranslational modifications (PTMs), including O-glycosylation,
N-glycosylation, 𝛾-carboxylation, sulfation, and phosphorylation [1–10]. FIX circulates in plasma as a zymogen that
is proteolytically activated to an enzyme, FIXa, during the
process of blood coagulation. The activation of FIX by FXIa
occurs on the platelet surface [11] and the resulting FIXa acts

on the platelet surface as part of a factor Xa- (FXa-) generating
enzyme complex [12]. FIXa alone has minimal ability to
activate factor X (FX), but when assembled into a metal iondependent complex with the cofactor, factor VIIIa (FVIIIa),
the complex efficiently activates FX to FXa. [13]. In a similar
manner, the resulting FXa forms an enzyme complex with
factor Va (FVa) that proteolytically activates prothrombin to
provide the burst of thrombin generation necessary for fibrin
clot formation [12]. The overall importance of FIX is indicated
by the fact that a deficiency of FIX results in a severe bleeding
disorder, hemophilia B [14].
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The preferred method of management of bleeding in
hemophilia B patients is administration of plasma-derived or
recombinant FIX products. While recombinant FIX products
are similar to the natural protein, none are identical in
every detail. Various posttranslational modifications are the
primary reason for such differences, but also of interest
is a polymorphism found in plasma-derived FIX [15]. The
polymorphism occurs at residue 148 with two identified
variants: Thr-148 and Ala-148. The relative proportion of
this polymorphism varies among populations, although Thr148 is always predominant [16]. To date, recombinant FIX
products have all been developed to be consistent with the
Ala-148 variant. In contrast, IXINITY (trenonacog alfa [coagulation factor IX (recombinant)]) is a new, FDA-licensed
recombinant human FIX with a primary amino acid sequence
having the predominant Thr-148 polymorphism.
Trenonacog alfa is produced in a Chinese Hamster Ovary
(CHO) cell line. The purification process is comprised of
chromatographic purification steps and three validated viral
inactivation/removal steps, which include solvent-detergent
treatment, a chromatographic step, and nanofiltration. The
purification process also contains a validated polishing step
for the reduction of CHO proteins.
In this study, trenonacog alfa was extensively characterized using a number of analytical techniques to assess
primary structure, higher order structure, function, and
purity.

Advances in Hematology
(4.6 mm × 100 mm; 3.5 𝜇m) installed on an Agilent 1100/1200
HPLC system in gradient mode. The starting mobile phase
was 95% A and 5% B, where “A” is 0.1% (v/v) trifluoroacetic
acid (TFA) in water and “B” is 0.1% TFA in 25% isopropyl
alcohol, 75% acetonitrile. A nonlinear gradient from 5% B to
52% B was performed over 67 minutes, followed by a wash
step with 100% B. The flow rate was 1 mL min−1 , and the
column was maintained at 30∘ C. A 25 𝜇g protein load was
used.
2.4. Host Cell Protein ELISA. Host cell proteins were quantified by a sandwich ELISA that incorporates the use of
an affinity-purified, sheep anti-host cell protein polyclonal
antibody for both capture and detection. The sheep antibody was produced by immunization with a preparation
of host cell proteins derived from a mock (null vector)
factor IX production run (Hematologic Technologies Incorporated, Essex Junction, VT). Samples or standards and the
horseradish peroxidase- (HRP-) conjugated detecting antibody were simultaneously dispensed onto assay plates passively coated with capture antibody and were allowed to bind.
The plate was then washed and the HRP substrate 3,3,5 ,5 tetramethylbenzidine (Sigma-Aldrich, St. Louis, MO) was
added to the plate. Following a short development step, the
reaction was quenched with sulfuric acid and the plate was
read at 450 nm. Absorbance was converted to concentration
using assay calibration standards that were also generated
from a null vector run.

2. Methods
2.1. One-Dimensional SDS-PAGE. SDS-PAGE was performed using NuPAGE® 12% or 4–12% gradient acrylamide gels
and 4x LDS sample buffer from Life Technologies (Grand
Island, NY). Samples were reduced with 𝛽-mercaptoethanol
(5% v/v final). Protein loads were 2 𝜇g/lane for standard
Coomassie Blue stained gels and 1.2 𝜇g/lane for kinetic experiments (also stained with Coomassie Blue). The MW marker
was SeeBlue® Plus 2 standard (Life Technologies). Gels were
run at 175 or 200 V for 68 or 53 minutes, respectively, in a
MOPS-buffered SDS running buffer (Life Technologies).
2.2. Gel Filtration Chromatography. GFC was performed
using a TSKgel® G3000SWXL column (7.8 mm × 30 cm; 5 𝜇m
particle size; Tosoh Bioscience (King of Prussia, PA)) on
an Agilent 1100/1200 HPLC system (Santa Clara, CA) held
at 22∘ C. Chromatography was performed at a flow rate of
0.5 mL min−1 , with a mobile phase of 50 mM Tris, 200 mM
NaCl, pH 7.5, in the presence and absence of 5 mM CaCl2 .
UV data were collected at 280 nm. A 40 𝜇g protein load was
used.
2.3. Reduced Reverse Phase HPLC. Samples were simultaneously denatured and reduced using guanidine hydrochloride
and dithiothreitol (6 M and 10 mM final concentration, resp.;
30 min at room temperature (RT)). Next, samples were
alkylated using 4-vinylpyridine (3 mM final concentration;
90 min at RT, protected from light). Chromatographic separation was performed using a Zorbax 300SB-C18 column

2.5. Nonactivated Partial Thromboplastin Time. Nonactivated partial thromboplastin times (NAPTTs) were measured
by European Pharmacopoeia (Ph. Eur.) method 2.6.22, Activated Coagulation Factors. Pass/fail was based on a threshold
clotting time of 150 s.
2.6. Chromogenic Assay for Residual FIXa. The BIOPHEN®
Factor IXa assay kit (Aniara Diagnostica, West Chester, OH)
was used in accordance with the manufacturer’s instructions
to quantify trace FIXa present in trenonacog alfa.
2.7. N-Terminal Sequencing. N-terminal sequencing was performed by Edman degradation using a Procise® Sequencer
(Applied Biosystems, Carlsbad, CA).
2.8. Peptide Mapping. LC-MS/MS peptide mapping was performed to confirm primary sequence and to identify and
quantitate PTMs. A LysC (Achro K, Wako, Osaka, Japan)
digest was performed for general sequence coverage. A
PNGase F plus trypsin digest was used to specifically analyze
the O-glycosylation, phosphorylation, and sulfation modifications of the activation peptide. For LysC digests, samples
were diluted in 50 mM ammonium bicarbonate buffer (pH
7.8), reduced with dithiothreitol (5 mM final), alkylated with
iodoacetamide (15 mM final), and then digested with LysC
(1 : 50 E : S, w : w) for 18 hours at 30∘ C. For trypsin digests,
samples were deglycosylated with PNGase F (New England
Biolabs, Ipswich, MA) using 0.5 U 𝜇g−1 of FIX for 2 hours
at 37∘ C, reduced and alkylated as described above, and then
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digested with trypsin (Promega; Fitchburg, WI; 1 : 50 E : S,
w : w) for 18 hours at 37∘ C. Digests were quenched to a final
0.5% formic acid concentration, aliquoted, and then frozen at
−80∘ C until LC-MS/MS analysis.
LC-MS/MS analysis was performed on a Dionex U3000
nanoLC system (Sunnyvale, CA) with an AB-Sciex 4000
QTrap® MS (Framingham, MA). Solvent A was 0.1% formic
acid (v/v) in deionized water. Solvent B was 0.1% formic acid
(v/v) in acetonitrile (Burdick and Jackson, Muskegon, MI).
Peptides were separated on a Dionex Acclaim Pepmap100 C18
column (75 𝜇m × 25 cm, 3 𝜇m particle size) with an Acclaim
Pepmap100 C18 trap column used to desalt and concentrate
the samples prior to separation (200 𝜇m × 1 cm, 5 𝜇m particle
size). The columns were preequilibrated with 100% A and
maintained at 45∘ C. After injection onto the trap column and
a 100% A wash, the valve was switched to separation mode,
and a linear gradient to 5% B over 5 minutes followed by a
linear gradient to 45% B over 200 minutes (250 nL min−1 )
was used to separate the peptides. MS data were acquired in
positive mode, with collision energies optimized to maximize
the information content of the MS/MS spectra.
TM

2.9. Circular Dichroism Spectroscopy. Trenonacog alfa samples (2.5 mg mL−1 ) were treated with 0.1 mg/mL Chelex® 100
(Bio-Rad, Hercules, CA) for approximately fifteen minutes
with gentle agitation and then centrifuged and filtered. Samples were then diafiltered and brought to a final concentration
of 1.0 mg/mL in 25 mM MOPS, 150 mM NaClO4 , 5 mM
CaCl2 , and pH 7.5. CD measurements were carried out using
a Jasco J-715 Spectropolarimeter (Easton, MD).
2.10. 𝛾-Carboxylation. 𝛾-Carboxylation was quantified by
strong anion exchange chromatography, as per Gillis et al.
with a gradient optimized for the chromatography system and
a decreased flow rate (0.5 mL min−1 ) [17].
2.11. FIX Clotting Assay. A FIX one-stage clotting assay was
performed on an ACL-TOP coagulation analyzer (Beckman
Coulter, Brea, CA). The aPTT reagent (HemosIL Synthasil),
FIX deficient plasma, and diluent were from Instrumentation
Laboratories (Bedford, MA). The assay was calibrated against
the British Working Standard for factors II, IX, and X (NIBSC
Catalog #07/326). Data were analyzed by the parallel line
method using PLA 2.0 software (Stegmann Systems, Rodgau,
Germany).
2.12. Rate of Activation by Factor XIa. The rate of FIX
activation by FXIa was determined using SDS-PAGE to
monitor the disappearance of the 55 kDa FIX band and
the appearance of the 45 kDa FIXa band in a time-course
experiment. FXIa was incubated with FIX at a mass ratio of
1 : 1,000, and samples were withdrawn at 5-minute intervals
and run on nonreducing SDS-PAGE gels with Coomassie
staining. Optical densities of the FIX and FIXa bands in each
sample were calculated as a proportion of the total optical
density of the lane. The relative proportions were plotted as a
function of time and fit by linear regression, where the slope
equaled the rate of conversion of FIX to FIXa.

2.13. Effect of Cofactor (FVIIIa) on FIXa Activity. The
enhancement of FIXa activity by FVIIIa was examined using
the Biophen Factor IX assay kit (Aniara Diagnostica, West
Chester, OH) in two separate trials: one where FVIIIa was
included in the assay reagent, and another where FVIIIa was
not included. Samples were assayed at two or more different
concentrations such that reaction rates could be calculated by
plotting assay results against FIXa concentration. The ratio of
slopes (rate with FVIIIa/rate without FVIIIa) was employed
to express the relative rate enhancement with the addition of
FVIIIa.
2.14. Conversion of FIX to FIXa. Several methods required
the complete conversion of FIX to FIXa. This was accomplished by incubating FIX with FXIa at an enzyme to substrate
ratio of 1 : 100 (w/w) for 40 minutes at 37∘ C. SDS-PAGE was
employed to confirm complete activation.
2.14.1. Inhibition of FIXa by Antithrombin. The efficiency
of antithrombin inhibition was determined by incubating
1.09 𝜇M FIXa with varying concentrations of antithrombin (0
to 1.4 𝜇M). The residual FIXa activity in each of the samples
was then measured using the Biophen FIXa assay kit (Aniara
Diagnostica, West Chester, OH). Residual FIXa activity was
plotted as a function of the antithrombin concentration and
data were then analyzed by linear regression.
2.15. Active-Site Titration. The number of active sites per
FIXa molecule was determined using the synthetic “burst”
reagent 4-nitrophenyl 4-guanidinobenzoate hydrochloride in
accordance with published methods [18].
2.16. Sialic Acid Quantitation. The N-acetylneuraminic acid
(Neu5Ac) content of trenonacog alfa was quantitatively
determined by the method of Anumula [19]. Samples and
standards were analyzed with triplicate mild acid hydrolyses.
Neu5Ac calibration standards went through the hydrolysis
reaction in parallel with the samples. The released sialic
acids were labeled with o-phenylenediamine (OPD) and then
separated by RP-HPLC (duplicate injections of each labeled
hydrolysate). A linear calibration curve was used to calculate
the total amount of Neu5Ac per mole of FIX.
2.17. N-Glycan Profile. N-glycan profiling was performed
according to the method described by Anumula and Dhume
[20]. Glycan populations were analyzed by MALDI-TOF-MS
to determine sialylation levels in each region of the normal
phase chromatogram.

3. Results
3.1. Purity. Purity of trenonacog alfa was assessed using a
panel of assays designed to detect high molecular weight
(HMW) species and proteolytic degradants. By SDS-PAGE
with Coomassie stain, under both reducing and nonreducing
conditions, only a single band at apparent molecular weight
57,000 Da was detected for each trenonacog alfa lot tested,
indicating that the dominant species in the preparations
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Figure 1: SDS-PAGE was performed using a NuPAGE 12% gel and
4x LDS sample buffer from Life Technologies (Grand Island, NY).
Reduced lanes were treated with 𝛽-mercaptoethanol to 5% of total
sample volume. 2 𝜇g of protein was loaded in each lane. Gels were
stained with Coomassie Blue. Lanes are (from left to right), SeeBlue
Plus 2 standard, lot 1, lot 2, lot 3, lot 4, lot 1 reduced, lot 2 reduced,
lot 3 reduced, lot 4 reduced, and SeeBlue Plus 2 standard. Molecular
weights corresponding to the standards are shown.

Native factor IX

0.10
0.05
0.00
6.00

was full length, unactivated FIX (Figure 1). The apparent
molecular weight is consistent with the mature plasmaderived protein, complete with the expected posttranslational
modifications. Trenonacog alfa was further analyzed by
gel filtration chromatography and high molecular weight
species were found to be present at very low levels (≤1.3%)
(Figure 2(a)). The presence of these species was confirmed by
analytical ultracentrifugation (data not shown). Trenonacog
alfa samples were also reduced and alkylated and then
subjected to reversed-phase HPLC analysis, which permitted
proteolytic degradants to be separated and quantified. Total
levels of proteolytic degradants were found to be ≤6%, where
FIXa light chain and heavy chain associated species made up
the majority of the detected material (approximately 2% and
3%, resp.). A truncated form of FIX (cleaved at C-terminus of
Arg318) made up the remaining approximately 1%. This form
has been previously reported in recombinant FIX products
[21].
Residual proteins from the expression host (Chinese
Hamster Ovary cells) were detected by sandwich ELISA,
using capture and detection antibodies raised against partially purified lysate from a null vector manufacturing run.
This method was developed to be highly sensitive to host
cell proteins that copurify in the trenonacog alfa manufacturing process. Using this ELISA, it was found that early
development lots (identified as IB1001) had detectable levels
of host cell protein. A change in the manufacturing process
was introduced for the current product (IXINITY) such that
the host cell protein levels were reduced a thousandfold.
Two assays were used to evaluate FIXa levels in
trenonacog alfa. The nonactivated partial thromboplastin
time assay (NAPTT), which is a universal test for the presence
of activated coagulation factors, yielded consistent results
on all lots tested and indicated only minimal contamination
with FIXa. Additionally, a commercially available, kit-based
colorimetric assay specific for FIXa was used to quantify

9.00

12.00

15.00
(min)

18.00

21.00

(b)

Figure 2: Gel filtration chromatography was performed using
a TSK-Gel G3000SWXL column run at 22∘ C at a flow rate of
0.5 mL min−1 . The column was run in 50 mM Tris, 200 mM NaCl,
and pH 7.5. 40 𝜇g of total protein was loaded on the column per run.
Absorbance at 280 nm is plotted against time in minutes. The upper
tracing shows trenonacog alfa run in the absence of calcium. The
lower tracing shows trenonacog alfa run in the presence of 5 mM
CaCl2 .

FIXa levels in seven lots of trenonacog alfa; measured values
were consistent from lot-to-lot and in the range of ≤0.0019 IU
FIXa/IU FIX.
3.2. Primary Structure and Posttranslational Modifications.
The primary structure for trenonacog alfa, including the threonine residue at position 148, was confirmed through peptide
mapping (AchroK, trypsin) and N-terminal sequencing (first
ten residues of the activation peptide). Mass spectrometry by
MALDI-TOF indicated a weight average molecular weight
of 54827 Da, which differs from the theoretical mass of the
amino acid sequence due to the numerous PTMs [22]; a
summary of the posttranslational modifications found in
trenonacog alfa is given in Table 1.
3.3. Higher Order Structure. Higher order structure was evaluated by circular dichroism (CD) spectroscopy in the presence of calcium ion; under these conditions, FIX is known
to undergo a conformational change, resulting in a more
ordered structure that is required for activity [23–25]. Both
secondary and tertiary structures were highly consistent, as
illustrated by the spectra obtained in both the near and far UV
for six trenonacog alfa lots (see Figure 3). The conformational
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Table 1: Posttranslational modifications in trenonacog alfa, nonacog alfa, and plasma-derived factor IX.
Posttranslational
modification
Disulfide bridging
𝛾-Carboxylation
𝛽-Hydroxylation
Sulfation
Phosphorylation

Trenonacog alfa

Nonacog alfa

Plasma-derived factor IX

Eleven disulfide bridges
≥11.7 mol 𝛾-carboxyglutamic
acid/mol factor IX

Eleven disulfide bridges
Eleven disulfide bridges [4]
11.5 mol 𝛾-carboxyglutamic acid/mol 12 mol 𝛾-carboxyglutamic acid/mol
factor IX [4]
factor IX [5]

50% 𝛽-hydroxylated at Asp64
Tyr155: low degree of sulfation
observed (5%)
Ser158: low degree of
phosphorylation observed (3%)

46% 𝛽-hydroxylated at Asp64
Tyr155: low degree of sulfation
observed
Ser158: low degree of
phosphorylation observed

∼40% 𝛽-hydroxylated at Asp64 [4]
Tyr155: high degree of sulfation
observed [4]
Ser158: ∼90% phosphorylated [6]

O-linked glycosylation
EGF domain

Ser53: Xyl1,2 -Glc
Ser61: Neu5Ac-Hex-HexNAc-Fuc

Low degree of site occupancy
observed (13%)
N-glycans are complex,
predominantly tri- and
N-linked glycosylation tetraantennary, and predominantly
sialylated; 80% of N-glycans are
either tetrasialylated or trisialylated
Activation peptide

Total sialylation

8.8 mol sialic acid/mol factor IX

Ser53: Xyl1,2 -Glc [7]
Ser53: Xyl1,2 -Glc [21]
Ser61: Neu5Ac-Gal-GlcNAc-Fuc
Ser61: Neu5Ac-Gal-GlcNAc-Fuc [21]
[7, 8]
Low degree of site occupancy
Low degree of site occupancy
observed [4]
observed [9]
N-glycans are complex,
predominantly tri- and
tetraantennary, and predominantly
sialylated [4]

N-glycans are complex,
predominantly tri- and
tetraantennary, and predominantly
sialylated [10]

6.5 mol sialic acid/mol factor IX [9]

8.8 mol sialic acid/mol factor IX [9]

Table 2: Functional characterization of trenonacog alfa.
Lot 1

Lot 2

Lot 3

Lot 4

Lot 5

Lot 6

Mean

216
256
247
269
249
242
247
Specific activity (IU/mg)
FIX activation rate (fraction FIXa band 0.0182
0.0199
0.0157
0.0185
0.0171
0.0137
0.0172
intensity−1 ⋅minute−1 )
Rate of increase in FIXa activity in
3
1.85 × 103
1.75 × 103 1.65 × 103 1.90 × 103
1.82 × 103
1.79 × 103
presence of FVIIIa relative to absence 1.79 × 10
of FVIIIa
Titration with AT; slope of inhibition −1.29 × 104 −1.53 × 104 −1.44 × 104 −1.81 × 104 −1.42 × 104 −1.44 × 104 −1.49 × 104
curve (mIU FIXa⋅mL−1 ⋅𝜇M AT−1 )

change was also verified by gel filtration chromatography,
where native FIX in trenonacog alfa samples elutes later in
the presence of calcium ion compared to its absence (see
Figure 2), even though the molecular masses are equivalent
by static light scattering (data not shown). The increased
elution time can be attributed to the lower hydrodynamic
volume of the more ordered conformation.
3.4. Functional Characterization. The functional properties
of trenonacog alfa were evaluated by a selected panel of in
vitro tests. An aPTT-based, single-stage, FIX clotting assay
was employed to measure potency relative to an appropriate
international standard for recombinant FIX. As illustrated in
Table 2, the six lots of trenonacog alfa tested yielded a mean
potency of 247 IU/mg with good overall lot-to-lot consistency
(RSD = 7.15%). To supplement the potency data, a set of
more discrete assays were employed to examine very specific
properties of the molecule. The various properties examined
included (a) the rate of activation by factor XIa; (b) the effect
the cofactor FVIIIa on the FIXa activity; (c) the efficiency

% RSD
7.15
12.9
4.86
11.7

of inhibition by antithrombin; and (d) the number of active
catalytic sites per molecule, once fully activated. The results
obtained from these various assays are presented in Table 2,
and in all cases, they yielded values that were (a) consistent
from lot-to-lot and (b) within a range that would be expected
for plasma-derived FIX.

4. Discussion
The standard of care for managing hemophilia B patients is
replacement therapy using recombinant or plasma-derived
FIX products. Although both recombinant and plasmaderived FIX products are viewed by most as equally safe
and efficacious, there are subtle differences that serve to
distinguish between products.
There is at least one prevalent polymorphism that has
been identified in FIX. Residue 148, the third residue in
the activation peptide, is either an alanine or a threonine
(Malmö polymorphism) [16]. Threonine is more common
at this position. Alanine is found in up to 35% of some

6
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Mean residue ellipticity
(deg·cm2 dmol−1 residue−1 )
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Figure 3: Circular dichroism spectroscopy was carried out in
25 mM MOPS, 150 mM NaClO4 , 5 mM CaCl2 , and pH 7.5 at approximately 1.0 mg mL−1 factor IX. CD measurements were carried out
with a 1 cm cell for near UV measurements and a 0.02 cm cell
for far UV measurements. Five accumulations were obtained per
spectrum. The spectrum of the buffer blank was subtracted from
the sample spectra; then the observed ellipticities were converted to
mean residue ellipticities using the protein concentration, the mean
residue weight (112.2 Da), and the path length of the cell. Near UV
spectra are shown in the upper panel. Far UV spectra are shown in
the lower panel. The spectra from six trenonacog alfa lots are shown
on each plot.

European populations, much lower frequency (3–7%) in
Asian populations, and is not seen at all in some African
populations [16]. There does not seem to be any selective
advantage to the mutation, and epitope mapping of inhibitors
from hemophilia B patients has not identified patient antibodies that recognize this site. In plasma-derived FIX, the
distribution of Ala/Thr would be expected to be representative of the population from whom the plasma is drawn.

Recombinant products BeneFIX (nonacog alfa [coagulation
factor IX (recombinant)]), which has been available for more
than fifteen years, and Rixubis (nonacog gamma [coagulation factor IX (recombinant)]), a relatively new product
licensed in 2013, both have alanine at residue 148. IXINITY
(trenonacog alfa [coagulation factor IX (recombinant)]) has
the more common threonine at residue 148.
Modern therapy is to give the highest purity product
possible. Plasma-derived FIX preparations can, unsurprisingly, contain other Gla-containing proteins including FVIIa
and FX, although these proteins were not detected in the
highest purity plasma-derived products [3, 26]. Preparations
of recombinant proteins do not contain other coagulation
factors but may contain proteins native to the cell line
producing the protein. Early in development, elevated levels
of host cell proteins were reported in trenonacog alfa (which
was identified in these reports as IB1001); this resulted in
seroconversion in a subset of patients [27]. Modifications to
the manufacturing process and the introduction of enhanced
test methods have ensured adequate removal of these proteins
in the current product. This is supported by clinical data,
as no new seroconversions have been identified in patients
receiving new product, and patients who had previously
seroconverted with measurable titers and who received
trenonacog alfa (IXINITY) have shown a decreasing trend in
titer values [28].
In preparations of both plasma-derived and recombinant
FIX, both higher and lower molecular weight contaminants
have also been observed [3, 26]. The purity of trenonacog
alfa in this study was consistent with previous reports for
FIX therapeutics [1, 4, 25, 29, 30]. Small amounts of higher
molecular weight products were present as were low levels
of material consistent with peptides resulting from cleavage
at Arg145 (carboxy terminal of light chain), Arg180 (amino
terminal of heavy chain), and Arg318. All sites are known to
be sensitive to cleavage by proteases [31].
The presence of light chain in this analysis suggests the
possibility that some of the protein might have been activated
during purification. The literature supports that there is a
correlation between high FIXa levels and thrombogenicity
in FIX preparations [29]. Residual FIXa has been identified
as a contaminant in FIX preparations, both plasma-derived
and recombinant [1, 4, 25, 29, 30]. Trenonacog alfa was
evaluated for FIXa levels. A chromogenic assay was used to
establish that levels of FIXa were low (≤0.0019 IU/IU FIX).
The role of these levels in promoting clotting was examined
by the standard European Pharmacopoeial method using
nonactivated partial thromboplastin times [32]. This assay
provides a threshold clotting time; clotting times shorter
than the threshold are regarded as being indicative of a
relevant enhancement of procoagulant activity. All samples
had clotting times longer than the threshold indicating that
the activity of the FIXa in these trenonacog alfa lots was below
the levels associated with thrombosis [33].
FIX undergoes extensive posttranslational modification.
In FIX, like the other vitamin K-dependent coagulation
proteins, a number of glutamic acid (Glu) residues in the
amino-terminal end of the molecule undergo modification
by addition of an extra carboxyl group. The addition of this
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carboxyl group produces gamma-carboxyglutamate (Gla)
[34]. In native human FIX, there are 12 such Gla residues [2].
This modification is necessary for calcium ion binding which
significantly alters the structure of FIX, enabling binding
to a negatively charged lipid surface [35]. Analysis of the
Gla content indicated essentially complete carboxylation of
trenonacog alfa (>11.7 mol Gla/mol FIX; 87% Gla-12 and 13%
Gla-10 + Gla-11 by strong anion exchange chromatography),
consistent with reported data for nonacog alfa (11.5 mol
Gla/mol FIX) [4]. The change in structure due to calcium ion
binding of the Gla domain was demonstrated by the decrease
in hydrodynamic volume measured by gel filtration of FIX in
the presence of calcium (Figure 2(b)).
A second important calcium ion binding site in FIX
is found in the junction between the Gla domain and
the first epidermal growth factor like (EGF) domain [23,
36]. Aspartic acid residue 64 is part of this calcium ion
binding site. In plasma-derived FIX, slightly fewer than
50% of FIX molecules have been modified at this residue
by beta-hydroxylation. Trenonacog alfa had measured betahydroxylation levels at least equivalent to the plasma-derived
and consistent with reported data for nonacog alfa [4].
A number of the posttranslational modification sites are
located in the activation peptide of FIX. Among those seen
in plasma-derived FIX are sulfation at residue 155 (tyrosine)
and phosphorylation at residue 158 (serine). Trenonacog
alfa, like other recombinant FIX preparations, showed low
levels of modification at these sites [37]. The role of these
modifications in FIX function is not clear. No point mutations
at either of these residues have been reported in the FIX mutation database [38]. When comparing the pharmacokinetic
properties of the first recombinant FIX product, nonacog alfa,
against plasma-derived, it was noted that recombinant FIX
had a lower in vivo recovery [39, 40]. It was suggested that
the reduced levels of sulfation and phosphorylation in recombinant FIX might be responsible for the lower recovery of
that product [39]. Interestingly, all recombinant FIX products
have low levels of sulfation and phosphorylation, but there is
no consistent correlation with pharmacokinetics of plasmaderived FIX, suggesting that sulfation and phosphorylation
do not play a critical role in determining pharmacokinetic
parameters [39, 41].
By contrast, glycosylation strongly affects recovery and
half-life of many proteins including FIX [41–43]. In FIX,
there are two potential N-linked and four potential O-linked
glycosylation sites in the activation peptide, and two potential
O-linked glycosylation sites in the EGF domain. The Nglycans of trenonacog alfa are of the complex classification,
highly branched, contain poly-N-acetyllactosamine repeats,
and are highly sialylated. These structural features are similar
to those found in plasma-derived FIX [10]. The O-glycans in
the EGF domain and the activation peptide of trenonacog
alfa are identical to those found in the corresponding sites
of plasma-derived factor IX and other recombinant factor
IX products [7, 8, 21]. In FIX, terminal sialic acid content is
important for the pharmacokinetics of FIX and removal of
the sialic acids dramatically reduces recovery and half-life of
FIX [44]. Consistent with these findings, a pharmacokinetic
study comparing trenonacog with nonacog alfa, which did
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not show a statistically significant difference between the two
recombinant products, did show that area under the curve
and other pharmacokinetic values correlate with the degree of
sialylation of the N-glycans [41]. In general, this suggests that
higher levels of sialylation should be associated with better
pharmacokinetics [41–43].
To be functional in vivo, FIX should be activated and the
activated form should bind to factor VIIIa to cleave factor X.
Activation of FIX was monitored on gels by the appearance
of heavy and light chain. The rate of appearance of activation
products in trenonacog alfa was consistent across all lots.
Titrating FIXa with a known concentration of antithrombin
indicated that greater than 90% of FIX was activated in
all of the trenonacog alfa lots examined. FIXa activity was
assessed as the ability of FVIIIa to accelerate FX activation.
The acceleration was consistent across all lots and reflective
of tight binding of the activated trenonacog alfa product to
FVIIIa with good activity toward FX [35].
The specific activity is a combined assessment of activation, activity, and regulation by antithrombin. Specific
activity is determined from a clotting assay done in contactactivated plasma and represents a comparison to native FIX in
normal pooled plasma. By definition, a protein (FIX) present
at 4 𝜇g/mL in normal plasma has a maximum specific activity
of 250 IU/mg. The trenonacog alfa lots that were evaluated
had a mean specific activity of 247 IU/mg with minimal lotto-lot variation (RSD = 7.15%). This value is consistent with
the reported specific activity of nonacog alfa (260 IU/mg) [4].
These specific-activity data support the fact that trenonacog
alfa performs in a manner that is consistent with a fully
functional, high quality FIX product.

5. Conclusions
The results indicate that IXINITY (trenonacog alfa [coagulation factor IX (recombinant)]) is a highly pure product with
a primary sequence and posttranslational modifications consistent with the common Thr-148 polymorphism of plasmaderived FIX. In vitro testing verified that trenonacog alfa
is fully functional in the coagulation cascade and that this
functionality is highly consistent lot-to-lot.
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